Ken Griffin
PRQR icon

Ken Griffin’s ProQR Therapeutics PRQR Stock Holding History

Ken Griffin’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.14M Buy
703,323
+120,101
+21% +$197K ﹤0.01% 7364
2025
Q4 		$1.18M Sell
583,222
-73,790
-11% -$172K ﹤0.01% 7036
2025
Q3 		$1.4M Buy
657,012
+277,749
+73% +$607K ﹤0.01% 6808
2025
Q2 		$774K Sell
379,263
-439,595
-54% -$715K ﹤0.01% 7643
2025
Q1 		$1.09M Buy
818,858
+410,051
+100% +$873K ﹤0.01% 6771
2024
Q4 		$1.08M Buy
408,807
+321,830
+370% +$1.02M ﹤0.01% 6845
2024
Q3 		$158K Buy
86,977
+68,612
+374% +$129K ﹤0.01% 10494
2024
Q2 		$30.5K Sell
18,365
-27,643
-60% -$53.7K ﹤0.01% 12255
2024
Q1 		$104K Sell
46,008
-31,808
-41% -$68K ﹤0.01% 11303
2023
Q4 		$154K Buy
+77,816
New +$120K ﹤0.01% 10342
2023
Q3 		– Sell
-116,792
Closed -$189K – 14923
2023
Q2 		$189K Buy
116,792
+17,013
+17% +$33.2K ﹤0.01% 9984
2023
Q1 		$213K Buy
+99,779
New +$305K ﹤0.01% 10081
2022
Q3 		– Sell
-209,215
Closed -$168K – 13382
2022
Q2 		$162K Buy
+209,215
New +$156K ﹤0.01% 10906
2022
Q1 		– Sell
-222,269
Closed -$745K – 14365
2021
Q4 		$1.78M Buy
222,269
+130,063
+141% +$990K ﹤0.01% 6513
2021
Q3 		$772K Buy
92,206
+34,076
+59% +$223K ﹤0.01% 8807
2021
Q2 		$392K Buy
58,130
+29,754
+105% +$192K ﹤0.01% 10617
2021
Q1 		$188K Buy
+28,376
New +$145K ﹤0.01% 11780
2019
Q4 		– Sell
-65,996
Closed -$380K – 9605
2019
Q3 		$380K Buy
65,996
+22,971
+53% +$183K ﹤0.01% 7212
2019
Q2 		$391K Sell
43,025
-39,314
-48% -$464K ﹤0.01% 7181
2019
Q1 		$1.14M Buy
82,339
+30,367
+58% +$454K ﹤0.01% 5365
2018
Q4 		$819K Buy
+51,972
New +$954K ﹤0.01% 5599
2016
Q1 		– Sell
-11,960
Closed -$103K – 7712
2015
Q4 		$103K Sell
11,960
-1,676
-12% -$19.3K ﹤0.01% 6643
2015
Q3 		$198K Buy
13,636
+634
+5% +$10.6K ﹤0.01% 6173
2015
Q2 		$217K Buy
13,002
+3,405
+35% +$64.1K ﹤0.01% 6213
2015
Q1 		$210K Buy
+9,597
New +$198K ﹤0.01% 6121
2014
Q4 		– Sell
-108,715
Closed -$1.87M – 8679
2014
Q3 		$1.87M Buy
+108,715
New +$1.74M ﹤0.01% 2915

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Ken Griffin's PRQR Position: Q1 2026 in Review

Ken Griffin increased its ProQR Therapeutics (PRQR) stake by 21% in Q1 2026, buying an estimated $197K and bringing the position to 703,323 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #7364.

Ken Griffin first reported a position in PRQR in Q3 2014 and has held it in 26 quarters since. The position peaked at $1.87M in Q3 2014. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

  • Ken Griffin held 703,323 shares of ProQR Therapeutics worth $1.14M as of Q1 2026.
  • Ken Griffin bought 120,101 ProQR Therapeutics shares in Q1 2026, an estimated $197K.
  • ProQR Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #7364 holding.
  • Ken Griffin first reported a position in ProQR Therapeutics in Q3 2014 and has held it in 26 quarters since.
  • Ken Griffin's ProQR Therapeutics position peaked at $1.87M in Q3 2014.
  • 69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.